entertainment -WSS

entertainment

author：comprehensive 2025-09-30 02:21:55 - browse：7

A woman walks in San Francisco, with her father who has Alzheimer's – public health and science coverage from STAT — Ben Margot/AP

A host of hurdles are slowing the adoption of the new Alzheimer’s drug Leqembi, experts involved in the treatment of patients said Wednesday, from complicated logistics to the fact that many people don’t recognize that their memory loss is a disease soon enough.

Some patients still grapple with whether they want to be diagnosed, even though a treatment exists, the experts said, speaking during a STAT virtual event.

“Even the word for dementia does not always exist in every culture and in every language,” said Hollis Day, chief of geriatrics at Boston Medical Center and a professor at Boston University’s medical school. “And so just getting people to accept that memory loss is not normal aging necessarily, is a big barrier to getting people into diagnosis early enough to benefit from these treatments.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Hospitals warn Medicare's drug payment fix is ‘unlawful’

hotspot

WSS

Medicare reduced heart disease by changing how it pays doctors

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

STAT Summit: Biotech founders on deal

The FDA weighs the risks of candy

Lawmakers consider Medicare pay reforms for doctors

Medtronic CEO on promising devices for diabetes, hypertension

Wikipedia

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

Hepatitis C has a cure — but many Americans still lack access to it

Eli Lilly expects to double planned employment in Boston center

23andMe had bad news about my health. I wish a person had delivered it

Medicare reduced heart disease by changing how it pays doctors

Hollywood unions extend contract negotiations for actors

STAT Readout Newsletter: Today's biggest biotech updates

As demand for Covid shots wanes, Moderna seeks its next success

HHS leader on health, climate change and biopharma emissions

Guidelines to prevent youth baseball injuries need more muscle

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

hotspot

FDA has safety concerns on CRISPR

UnitedHealth’s board chair also owns a personal investment firm

Pharmacists can make shortage drugs, but at what cost?

UnitedHealth’s board chair also owns a personal investment firm

STAT Summit: Michael J. Fox on progress in Parkinson's research

FDA gives detailed accounting of AI

hotspot

hotspot

entertainment

focus